Journal of Cardiac Failure
Volume 13, Issue 9 , Pages 752-758 , November 2007

Serum Matrix Metalloproteinase-3 as a Novel Marker for Risk Stratification of Patients With Nonischemic Dilated Cardiomyopathy

Received 12 December 2006 ,Revised 22 June 2007 ,Accepted 29 June 2007.

References 

  1. Weber KT, Anversa P, Armstrong PW, Brilla CG, Burnett JC, Cruickshank JM, et al. Remodeling and reparation of the cardiovascular system. J Am Coll Cardiol. 1992;20:3–16
  2. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling: concepts and clinical implications: a consensus paper from international forum on cardiac remodeling. J Am Coll Cardiol. 2000;35:569–582
  3. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997;96:509–516
  4. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation. 2003;107:1231–1233
  5. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF. Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross-links. Am J Pathol. 1996;148:1639–1648
  6. Nelson AR, Fingleton B, Rotheenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18:1135–1149
  7. Stetler-Stevenson WG. Dynamics of matrix turnover during pathologic remodeling of the extracellular matrix. Am J Pathol. 1996;148:1345–1350
  8. Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, et al. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation. 2002;105:753–758
  9. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ, Spinale FG. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation. 1998;97:1708–1715
  10. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, et al. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944–1949
  11. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee-Jackson D, Bozkurt B, et al. Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail. 2002;8:390–398
  12. Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hara Y, Shigematsu Y, et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-α in patients with idiopathic dilated cardiomyopathy and effect of carvedilol on these levels. Am J Cardiol. 2003;91:1024–1027
  13. Gerad-Mizon F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P, et al. Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the etiology of left ventricular systolic dysfunction. Eur Heart J. 2004;25:688–693
  14. Ohtsuka T, Hamada M, Hiasa G, Sasaki O, Suzuki M, Hara Y, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:412–417
  15. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072–1083
  16. Spinale FG. Matrix metalloproteinases. Regulation and dysregulation in the failing heart. Circ Res. 2002;90:520–530
  17. Hojo Y, Ikeda U, Ueno S, Arakawa H, Shimada K. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J. 2001;65:71–75
  18. Kai H, Ikeda H, Yusakawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteinase-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368–372
  19. Ries C, Petrides PE. Cytokine regulation of matrix metalloproteinase activity and regulatory dysfunction in disease. Biol Chem. 1995;376:345–355
  20. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378:151–160
  21. Banfi C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J. 2005;26:481–488
  22. Murphy G, Coclett MI, Stephens PE, Smith BJ, Docherty AJ. Stromelysin is an activator of procollagenase. A study with natural and recombinant enzymes. Biochem J. 1987;248:265–268
  23. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyar DB, et al. Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures. The Framingham Heart Study. Circulation. 2004;109:2850–2856
  24. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–1585
  25. Dec GW, Fuster V. Medical process: idiopathic dilated cardiomyopathy. N Engl J Med. 1994;331:1564
  26. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J. 2004;147:324–330
  27. Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, et al. Epidemiologic and clinical characteristics of cardiomyopathies in Japan. Results from nation wide surveys. Circ J. 2002;66:323–336
  28. Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden. Eur Heart J. 2004;25:300–307

PII: S1071-9164(07)00957-8

doi: 10.1016/j.cardfail.2007.06.730

Journal of Cardiac Failure
Volume 13, Issue 9 , Pages 752-758 , November 2007

Article Tools

* Image Usage & Resolution